Floatz logo

Eribulin

Locally Recurrent Breast Cancer

Sun Yat-sen UniversitySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Locally Recurrent Breast Cancer cohort.

Asset / SponsorPhaseRating
Etirinotecan Pegol
Nektar Therapeutics
Phase 3BB
Balixafortide
Spexis AG
Phase 3B
ig-001
Sorrento Therapeutics, Inc.
N/AD

Same molecule, other indications

Eribulin is also rated in:

breast cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →